1st, October 2018
From September 25 to 27, the meeting organized by ASEBIO and the Junta de Andalucía brought together in Seville the largest national and international agents in the biotechnology sector.
PROALT has participated in the partnering event and met during these days with investors, customers and potential commercial and technological partners.
The company has presented advances in the area of colorectal cancer diagnosis, including preliminary data from validation of the developed COLODETECT® test prototypes.
PROALT has also presented to investors and potencial partners the latest advances in its project of therapeutic antibodies for the treatment of metastatic colorectal cancer, especially those related to the recent humanization of hPA-0661, its most advanced candidate currently in pre-clinical phases.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.